Skip to main content

Market Overview

Calithera, Antengene Announce Licensing Agreement For CB-708 In Cancer Settings

Share:
Calithera, Antengene Announce Licensing Agreement For CB-708 In Cancer Settings
  • Calithera Biosciences Inc (NASDAQ: CALA) and Antengene Corporation Ltd have announced an exclusive, worldwide license agreement for the development and commercialization of CB-708.
  • CB-708 is a highly potent, selective, orally-bioavailable small molecule inhibitor of CD73, currently in preclinical development for oncology.
  • Under the terms of the license agreement, Calithera will receive an upfront payment and potential milestone payments of up to $255 million.
  • Additionally, Calithera is eligible to receive tiered royalties on sales of the licensed product up to low double-digits.
  • Price Action: CALA shares are up 6.7% at $2.17 on the last check Monday.
 

Related Articles (CALA)

View Comments and Join the Discussion!

Posted-In: Briefs cancerBiotech News Penny Stocks Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com